Kurt Rasmussen

Kurt Rasmussen is the Chief Scientific Officer at Delix Therapeutics, a new company focused on developing neuroplasticity-promoting therapeutics for multiple neuropsychiatric indications. His career spans 30 years of highly innovative scientific the research in neuroscience pharmaceutical discovery, from hypothesis generation to clinical candidate evaluation. At the National Institute on Drug Abuse’s Division of Therapeutics & Medical Consequences, he directed the Medications Development Program, and played an integral role in evaluating the safety and efficacy of pharmacotherapies, behavioral therapies, and devices to treat substance use disorders. He previously served as Head in Neuroscience Research at Eli Lilly where he contributed to understanding the neural mechanisms underlying the clinical efficacy of Prozac, Zyprexa, Strattera, and Symbyax.
A Fellow in the American College of Neuropsychopharmacology, Dr. Rasmussen has amassed over 100 publications and patents. He received his B.A. with honors and dist inction from Cornell University, his Ph.D. in neuroscience and psychology from Princeton University, and was a postdoctoral associate in the Department of Psychiatry at the Yale University School of Medicine.